1
|
Tarhini A, Coleman S, El Naqa I, Sukrithan V, Aakrosh R, McCarter M, Carpten J, Colman H, Ikeguchi A, Puzanov I, Arnold S, Churchman M, Hwu P, Conejo-Garcia J, Dalton W, Weiner G, Tan A. 18P Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
2
|
Switzer B, Puzanov I. Tavokinogene telsaplasmid. DNA-based interleukin-12 (IL-12), Gene therapy, Treatment of metastatic melanoma, Treatment of triple-negative breast cancer, Treatment of head and neck cancer. DRUG FUTURE 2022. [DOI: 10.1358/dof.2022.47.6.3367991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Ribas A, Chesney J, Long G, Kirkwood J, Dummer R, Puzanov I, Hoeller C, Gajewski T, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin S, Ferrucci P, Diede S, Anderson J, Treichel S, Chan E, Hodi F, Gogas H. 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1422] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Haymaker C, Andtbacka R, Johnson D, Shaheen M, Rahimian S, Chunduru S, Gabrail N, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1207] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Babiker H, Borazanci E, Subbiah V, Algazi A, Schachter J, Lotem M, Hendler D, Rahimian S, Minderman H, Haymaker C, Bernatchez C, Murthy R, Hultsch R, Caplan N, Woodhead G, Hennemeyer C, Chunduru S, Anderson P, Diab A, Puzanov I. 1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
6
|
Puzanov I, Havenith K, Boni J, Cruz H, Anderson K, Kopotsha T, Le Bruchec Y, Bendell J, Kummar S, Papadopoulos K, LoRusso P, Wuerthner J. 1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
7
|
Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 2020; 31:724-744. [PMID: 32194150 DOI: 10.1016/j.annonc.2020.03.285] [Citation(s) in RCA: 116] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 03/03/2020] [Accepted: 03/07/2020] [Indexed: 02/08/2023] Open
Abstract
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been excluded from immunotherapy clinical trials because of concerns for high susceptibility to the development of severe adverse events resulting from exacerbation of their preexisting ADs. However, a growing body of evidence indicates that immune-checkpoint inhibitors (ICIs) may be safe and effective in this patient population. However, baseline corticosteroids and other nonselective immunosuppressants appear to negatively impact drug efficacy, whereas retrospective and case report data suggest that use of specific immunosuppressants may not have the same consequences. Therefore, we propose here a two-step strategy. First, to lower the risk of compromising ICI efficacy before their initiation, nonselective immunosuppressants could be replaced by specific selective immunosuppressant drugs following a short rotation phase. Subsequently, combining ICI with the selective immunosuppressant could prevent exacerbation of the AD. For the most common active ADs encountered in the context of cancer, we propose specific algorithms to optimize ICI therapy. These preventive strategies go beyond current practices and recommendations, and should be practiced in ICI-specialized clinics, as these require multidisciplinary teams with extensive knowledge in the field of clinical immunology and oncology. In addition, we challenge the exclusion from ICI therapy for patients with cancer and active ADs and propose the implementation of an international registry to study such novel strategies in a prospective fashion.
Collapse
Affiliation(s)
- J Haanen
- Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands
| | - M S Ernstoff
- Roswell Park Comprehensive Cancer Center, Buffalo, USA
| | - Y Wang
- Department of Gastroenterology, Hepatology & Nutrition, University of Texas MD Anderson Cancer Center, Houston, USA
| | - A M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia
| | - I Puzanov
- Roswell Park Comprehensive Cancer Center, Buffalo, USA
| | - P Grivas
- University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, USA
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, UK
| | - S Peters
- Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV) and Lausanne University, Lausanne, Switzerland
| | - J A Thompson
- University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, USA; National Cancer Institute/NIH, Bethesda, USA
| | - M Obeid
- Department of Medicine, Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Vaccine and Immunotherapy Center, Centre Hospitalier Universitaire Vaudois (CHUV), Centre d'Immunothérapie et de Vaccinologie, Lausanne, Switzerland.
| |
Collapse
|
8
|
Babiker H, Borazanci E, Subbiah V, Maguire O, Rahimian S, Minderman H, Haymaker C, Bernatchez C, Bindra G, Iverson I, Chunduru S, Anderson P, Puzanov I, Diab A. Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Chesney J, Puzanov I, Collichio F, Singh P, Milhem M, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbe C, Yi M, Sharma A, Mehnert J. Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.067] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Gandhi S, Gil M, Khoury T, Takabe K, Puzanov I, Gelman I, D'Assoro A, Opyrchal M. Abstract P2-06-17: A novel interaction of AURKA with MAPK pathway in breast cancer cells as a potential therapeutic target. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-06-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aurora A (AURKA) is a mitotic kinase responsible for centrosome segregation and mitotic spindle formation. In normal cells, expression of AURKA is highly regulated and is predominantly restricted to G2/M phases of the cell cycle. Unlike healthy cells, cancer cells overexpress AURKA through all phases of the cell cycle resulting in the acquisition of alternate non-mitotic functions. Little is known about cellular functions regulated by AURKA and its interaction with other signaling molecules. Here, we report a novel interaction between AURKA and the mitogen-activated protein kinase (MAPK) pathway at the level of MEK1 in breast cancer cells. This interaction may serve as a novel target as well as demonstrate by an additive cytotoxic effect of AURKA- and MEK1/2-specific inhibitors against estrogen positive (ER+) and triple negative breast cancer (TNBC) cells.
Results: We show that treatment of ER+ HER2- MCF-7, ER- HER2+ SKBR3 and ER- HER2- BT549 cells with AURKA specific inhibitors alisertib, MK8745 and Aurora A Inhibitor I resulted in over 2-fold increase in relative levels of poMEK1/2 and poERK1/2 compared to untreated controls. The activation of the MAPK pathway was rapid with changes seen within 5 min after treatment with AURKA inhibitors and was sustained for at least 48 hours. Treatment with the pan RAF inhibitor TAK-632 did not diminish alisertib-induced poERK and poMEK1/2. Alternatively, treatment with the MEK1/2 specific inhibitor PD0325901 completely abrogated alisertib-induced phosphorylation of MEK1/2 and ERK1/2. In situ proximity ligation and pull down assays demonstrated AURKA and MEK1/2 direct interaction. In vitro kinase assay showed direct phosphorylation of MEK1 by AURKA. Combined treatment of alisertib and PD0325901 in vitro revealed significant additive cytotoxic effect in MCF-7 and BT549 cells when compared to either agent used alone (p< 0.008 and p<0.011; p <0.04 and p<0.028) with early trend toward significance in survival in a BT549 xenograft breast cancer in vivo model.
Conclusions: Our data shows a novel AURKA-MEK1 interaction in breast cancer cells. In depth in vivo analysis is ongoing. The results reveal a promising new strategy for the treatment TNBC patients using a combination of AURKA and MEK1/2 inhibitors.
Citation Format: Gandhi S, Gil M, Khoury T, Takabe K, Puzanov I, Gelman I, D'Assoro A, Opyrchal M. A novel interaction of AURKA with MAPK pathway in breast cancer cells as a potential therapeutic target [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-06-17.
Collapse
Affiliation(s)
- S Gandhi
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - M Gil
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - T Khoury
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - K Takabe
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - I Puzanov
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - I Gelman
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - A D'Assoro
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - M Opyrchal
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| |
Collapse
|
11
|
Diab A, Haymaker C, Bernatchez C, Andtbacka R, Shaheen M, Johnson D, Markowitz J, Puzanov I, Murthy R, Johnson D, James M, Chunduru S, Geib J, Swann S, Rahimian S, Hwu P. Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Dy G, Dozier A, Reid M, Lee K, Miller A, Wallace P, Puzanov I, Opyrchal M, Ernstoff M, Johnson C, Mazorra Z, Saavedra D, Leon K, Lage A, Crombet T. P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1250] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5:95. [PMID: 29162153 PMCID: PMC5697162 DOI: 10.1186/s40425-017-0300-z] [Citation(s) in RCA: 1239] [Impact Index Per Article: 177.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Accepted: 11/06/2017] [Indexed: 02/06/2023] Open
Abstract
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.
Collapse
Affiliation(s)
- I Puzanov
- Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA
| | - A Diab
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - K Abdallah
- Merck & Co., Inc., Upper Gwynedd, PA, USA
| | - C O Bingham
- Johns Hopkins University, Baltimore, MD, USA
| | - C Brogdon
- Bristol-Myers Squibb Company, New York, NY, USA
| | - R Dadu
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - L Hamad
- Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA
| | - S Kim
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - M E Lacouture
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - N R LeBoeuf
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA
| | - D Lenihan
- Washington University in St Louis, St Louis, MO, USA
| | - C Onofrei
- Indiana University, Indianapolis, IN, USA
| | - V Shannon
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - R Sharma
- Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA
| | - A W Silk
- Massachusetts General Hospital, Boston, MA, USA
| | - D Skondra
- University of Chicago, Chicago, IL, USA
| | | | - Y Wang
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - K Wiley
- Oncology Nursing Society, Pittsburgh, PA, USA
| | - H L Kaufman
- Massachusetts General Hospital, Boston, MA, USA
| | - M S Ernstoff
- Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA.
| |
Collapse
|
14
|
Xu W, Frederickson J, Callahan J, Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski T, Puzanov I, Daud A, Colburn D, Choong N, Wongchenko M, Hicks R, McArthur G. Prognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Daud A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi F, Schachter J, Sosman J, Pavlick A, Gonzalez R, Blank C, Cranmer L, O’Day S, Salama A, Margolin K, Yang J, Homet Moreno B, Ibrahim N, Ribas A. Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Mehnert J, Rugo H, O'Neil B, Santoro A, Schellens J, Cohen R, Doi T, Ott P, Pishvaian M, Puzanov I, Aung K, Hsu C, Le Tourneau C, Soria JC, Elez E, Tamura K, Gould M, Zhao G, Stein K, Piha-Paul S. Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Diab A, Hurwitz M, Tannir N, Bernatchez C, Haymaker C, Bentebibel S, Curti B, Wong M, Gergel I, Tagliaferri M, Zalevsky J, Hoch U, Aung S, Imperiale M, Cho D, Tykodi S, Puzanov I, Kluger H, Hwu P, Sznol M. PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Long G, Blank C, Ribas A, Mortier L, Carlino M, Lotem M, Lorigan P, Neyns B, Petrella T, Puzanov I, Richtig E, O’Day S, Masucci G, Lebbe C, Steven N, Lutzky J, Hille D, Ebbinghaus S, Ibrahim N, McNeil C. Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30482-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer L, Robert C, Pavlick A, Gonzalez R, Hodi F, Ascierto P, Salama A, Margolin K, Gangadhar T, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.02] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Atkins M, Plimack E, Puzanov I, Fishman M, McDermott D, Cho D, Vaishampayan U, George S, Olencki T, Tarazi J, Rosbrook B, Fernandez K, Keefe S, Choueiri T. Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.01] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Chesney J, Collichio F, Andtbacka R, Puzanov I, Glaspy J, Milhem M, Hamid O, Cranmer L, Saenger Y, Ross M, Chen L, Kim J, Kaufman H. Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.04] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
|
22
|
Arenberger P, Fialova A, Gkalpakiotis S, Pavlikova A, Puzanov I, Arenbergerova M. Melanoma antigens are biomarkers for ipilimumab response. J Eur Acad Dermatol Venereol 2016; 31:252-259. [PMID: 27557295 DOI: 10.1111/jdv.13940] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Accepted: 06/29/2016] [Indexed: 11/27/2022]
Abstract
BACKGROUND Novel immunotherapy modalities significantly improve survival of patients with metastatic melanoma. However, CTLA-4-blocking monoclonal antibody ipilimumab is effective only in a small proportion of patients. Biomarkers for prediction of treatment response are indispensably needed. OBJECTIVE To determine the utility of multimarker detection of circulating melanoma cells as prognostic and pharmacodynamic biomarker in patients with metastatic melanoma treated with ipilimumab. METHODS Patients (n = 62) with metastatic melanoma in unresectable stage III or metastatic stage IV treated with ipilimumab were recruited prospectively. The values of four melanoma markers on circulating cells Melan-A, gp100, MAGE-3 and melanoma inhibitory antigen prior to the treatment and within the therapy were compared to the data collected at baseline - after the melanoma surgery. RESULTS The immunotherapy pretreatment marker level was found to be prognostic of overall survival; lower levels were linked to longer survival time. Moreover, longitudinal follow-up of melanoma markers in patients treated with ipilimumab correlates with therapy response. A decline of marker levels by >30% at week 6 (in 83% of the responding subjects) to week 9 (in all responders) of ipilimumab administration was associated with response to therapy. Elevation of the tumour markers during the treatment precedes clinical progression and gives an early warning of treatment failure. CONCLUSION Melanoma circulating cells hold potential as predictive and pharmacodynamic biomarker of immunotherapy.
Collapse
Affiliation(s)
- P Arenberger
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic
| | - A Fialova
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic
| | - S Gkalpakiotis
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic
| | - A Pavlikova
- Institute for Laboratory Diagnostics, Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic
| | - I Puzanov
- Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - M Arenbergerova
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic
| |
Collapse
|
23
|
Voss M, Gordon M, Mita M, Rini B, Makker V, Macarulla T, Smith D, Kwak E, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel M, Neuwirth R, Zohren F, Infante J. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30217-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
24
|
Andtbacka R, Kaufman H, Collichio F, Amatruda T, Nemunaitis J, Chesney J, Puzanov I, Harrington K, Zhang Y, Chen L, Shilkrut M, Ross M. 3334 Durable complete responses (CR) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31852-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Arenbergerova M, Fialova A, Gkalpakiotis S, Kodet R, Jancarkova T, Novotna M, Hess A, Puzanov I, Arenberger P. Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma. J Eur Acad Dermatol Venereol 2015; 30:1626-7. [DOI: 10.1111/jdv.13227] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M. Arenbergerova
- Department of Dermatovenereology; Third Faculty of Medicine; Charles University; Prague 10 Czech Republic
| | - A. Fialova
- Department of Dermatovenereology; Third Faculty of Medicine; Charles University; Prague 10 Czech Republic
| | - S. Gkalpakiotis
- Department of Dermatovenereology; Third Faculty of Medicine; Charles University; Prague 10 Czech Republic
| | - R. Kodet
- Department of Pathology and Molecular Medicine; 2nd Faculty of Medicine; Charles University; Prague 5 Czech Republic
| | - T. Jancarkova
- Department of Hematology; Third Faculty of Medicine; Charles University; Prague 10 Czech Republic
| | - M. Novotna
- Department of Radiodiagnostics; Liberec Hospital; Liberec Czech Republic
| | - A. Hess
- Division of Hematology - Oncology; Vanderbilt University Medical Center; Nashville TN USA
| | - I. Puzanov
- Division of Hematology - Oncology; Vanderbilt University Medical Center; Nashville TN USA
| | - P. Arenberger
- Department of Dermatovenereology; Third Faculty of Medicine; Charles University; Prague 10 Czech Republic
| |
Collapse
|
26
|
Yan Y, McArthur G, Gajewski T, Puzanov I, Hamid O, Gonzalez R, Wang Y, Lu S, Wongchenko M, Choong N, Ribas A. Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600 Mutation–Positive Locally Advanced or Metastatic Melanoma from Brim7 Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Collichio F, Milhem M, Andtbacka R, Puzanov I, Saenger Y, Chesney J, Cranmer L, Hamid O, Logan T, Glaspy J, Lebbé C, Garbe C, Gansert J, Li A, Chou J, Kaufman H. A Phase 1B/2, Multicenter, Open Label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec (T-Vec) and Ipilimumab (Ipi) Versus Ipi Alone in Previously Untreated, Unresected, Stage Iiib, Iiic, and Iv Melanoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012; 23:3137-3143. [PMID: 22700990 DOI: 10.1093/annonc/mds145] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed. PATIENTS AND METHODS Data on mRCC patients treated with sunitinib or sorafenib were obtained from the Czech Clinical Registry of Renal Cell Cancer Patients. Outcomes of patients who developed hand-foot syndrome (HFS) of any grade and/or grade 3/4 rash during the treatment were compared with patients without HFS and no, mild, or moderate rash. RESULTS The cohort included 705 patients treated with sunitinib and 365 patients treated with sorafenib. For sunitinib, the median overall survival (OS) was 43.0 months versus 31.0 months (P = 0.027) and median progression-free survival (PFS) 20.8 months versus 11.1 months (P = 0.007) for patients with versus without dermatologic toxicity, respectively. For sorafenib, the median OS and PFS were 27.9 and 24.6 months (P = 0.244), and 12.2 and 8.8 months (P = 0.050), respectively. In multivariable Cox regression, the skin toxicity was significantly associated with longer OS in the sunitinib cohort. CONCLUSION The presence of skin toxicity is associated with improved OS and PFS in patients with mRCC treated with sunitinib.
Collapse
Affiliation(s)
- A Poprach
- Masaryk Memorial Cancer Institute of Oncology, Brno, Czech Republic
| | - T Pavlik
- Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
| | - B Melichar
- Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
| | - I Puzanov
- Vanderbilt University Medical Center, Nashville, USA
| | - L Dusek
- Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
| | - Z Bortlicek
- Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
| | - R Vyzula
- Masaryk Memorial Cancer Institute of Oncology, Brno, Czech Republic
| | - J Abrahamova
- Department of Oncology and 1st Faculty of Medicine, Thomayer University Hospital and Charles University, Prague, Czech Republic
| | - T Buchler
- Department of Oncology and 1st Faculty of Medicine, Thomayer University Hospital and Charles University, Prague, Czech Republic.
| |
Collapse
|
29
|
Kelley M, Richmond A, Chase S, Gecewich A, Crandall H, Hooks M, Puzanov I, Sosman J. 270 The Impact of a Tissue Acquisition Program On Research in Molecular Targeted Therapy of Melanoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72068-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Gonzalez R, Ribas A, Daud A, Pavlick A, Gajewski T, Puzanov I, Teng M, Chan I, Choong N, McArthur G. Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34336-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
31
|
Long G, Sosman J, Daud A, Weber J, Flaherty K, Infante J, Hamid O, Schuchter L, Cebon J, Puzanov I, Algazi A, Kudchakar R, Lewis K, Hwu W, Kefford R, Sun P, Little S, Gonzalez R, Patel K, Kim K. Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34335-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
32
|
Rixe O, Puzanov I, LoRusso P, Yin J, Doroumian S, Zhi X, Olszanski A. Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33059-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
33
|
Donskov F, Michaelson M, Puzanov I, Davis M, Bjarnason G, Motzer R, Lin X, Cohen D, Wiltshire R, Rini B. Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33370-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
34
|
Arenbergerová M, Puzanov I. [BRAF mutation: a novel approach in targeted melanoma therapy]. Klin Onkol 2012; 25:323-328. [PMID: 23102192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The incidence of malignant melanoma is increasing worldwide, despite our best efforts in prevention and early detection. The locally advanced disease may be treated surgically with good results, however, metastatic melanoma is considered to be one of the most therapeutically challenging malignancies. The increasing knowledge of molecular changes in melanoma may change this picture. Malignant melanoma is not a singular, homogeneous disease but rather a mixture of subtypes characterized by specific mutations. Tumors with C-KIT mutation respond to therapy with C-KIT kinase inhibitor imatinib and the ones characterized by BRAF mutations respond to BRAF kinase inhibitor vemurafenib. Vemurafenib was approved by US FDA in 2011 and EMA in 2012 for therapy of patients with advanced melanoma, harboring mutation in BRAFV600E gene. Ipilimumab, an antibody to cytotoxic T-lymphocyte antigen 4 (CTLA-4), was registered in 2011 by both US FDA and European Medicines Agency for treatment of metastatic melanoma. This therapy promotes the anti-tumor T-cell activity by blocking a CTLA-4 antigen, a key negative regulator of immune response.
Collapse
|
35
|
Margolin K, Hodi F, McDermott D, Lawrence D, Hamid O, Puzanov I, Thompson J, Ernstoff M, Michener T, Heller K. 9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72515-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, Amaravadi RK, Lee RJ, Nolop KB, Puzanov I. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8519] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Sharfman WH, Hodi FS, Lawrence DP, Flaherty KT, Amaravadi RK, Kim KB, Dummer R, Gobbi S, Puzanov I, Sosman JA, Dohoney K, Lam LP, Kakar S, Tang Z, Krieter O, Atkins MB. Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8508] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Adjei AA, Sosman JA, Martell RE, Dy GK, Goff LW, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, Schwartz BE, Puzanov I. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3034] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Ribas A, Kim KB, Schuchter LM, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Flaherty KT, Moschos SJ, Lawrence DP, Hersey P, Kefford RF, Chmielowski B, Puzanov I, Li J, Nolop KB, Lee RJ, Joe AK, Sosman JA. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8509] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
McArthur GA, Ribas A, Chapman PB, Flaherty KT, Kim KB, Puzanov I, Nathanson KL, Lee RJ, Koehler A, Spleiss O, Bollag G, Wu W, Trunzer K, Sosman JA. Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8502] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Kwa M, Baumgartner RA, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Hung A, Jones H, Gabizon A, Muggia F. Treatment-related microangiopathic glomerulopathy and severe chronic kidney disease (CKD) in recurrent epithelial ovarian cancer (rEOC): A possible relationship with pegylated liposomal doxorubicin (PLD). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Lacouture ME, Chapman PB, Ribas A, Sosman JA, McArthur GA, Flaherty KT, Kim KB, Puzanov I, Nolop KB, Joe AK, Spleiss O, Koehler A, Wu W, Robert C, Hauschild A, Schadendorf D, Troy JL, Duvic M, Trunzer K. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8520] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Anthony SP, Puzanov I, Lin PS, Nolop KB, West B, Von Hoff DD. Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3093] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Puzanov I, Michaelson MD, Cohen DP, Li S, Burnett P, Desai J. Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21113] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Michaelson MD, Cohen DP, Li S, Motzer RJ, Escudier B, Barrios CH, Burnett PE, Puzanov I. Hand–foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.320] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
320 Background: HFS and related skin toxicities are common side effects of tyrosine kinase inhibitors such as SU, a multitargeted inhibitor of VEGF and PDGF receptors plus other receptor tyrosine kinases. In a randomized phase III trial of treatment-naïve mRCC pts, SU showed superior progression-free survival (PFS) and objective response rate (ORR) over interferon-alfa, with a median PFS of 11 mo and median overall survival (OS) of 26.4 mo, establishing SU as a reference standard of care (Motzer et al, 2009). In this retrospective analysis, correlations between SU-associated HFS and efficacy endpoints were investigated in mRCC pts from 5 clinical trials in the first- and second-line treatment settings. Methods: Analyses included pooled data from 770 pts who received single-agent SU as 50 mg/d on a 4-week-on/2-week-off schedule (n=544; 71%) or 37.5 mg continuous once-daily dosing (n=226; 29%). Median PFS and OS were estimated by Kaplan–Meier methods and compared between pts with vs without HFS using a log-rank test. ORR was compared by Pearson's chi-square test. Tumor response was assessed by investigators and adverse events were recorded regularly. Multivariate and time-dependent covariate analyses were performed. Results: Of 770 pts, 179 (23%) developed any-grade HFS, compared with 591 (77%) who did not. Most instances of HFS (63%) initially occurred during the first 3 treatment cycles. Pts who developed HFS had significantly better ORR (55.6% vs. 32.7%), PFS (14.3 vs. 8.3 mo), and OS (38.3 vs. 18.9 mo) than pts who did not develop HFS (p<0.0001). In a multivariate analysis, SU-associated HFS remained a significant independent predictor of both PFS and OS (and of OS by time-dependent covariate analysis). Conclusions: In mRCC pts, SU-associated HFS was significantly and independently associated with improved clinical outcomes. Overall, pts who did not develop HFS still had substantial benefit from SU. However, the presence of HFS identified a subset of pts that manifested highly favorable efficacy results with SU. These findings suggest that development of HFS may serve as a predictive biomarker of SU efficacy, although prospective validation is warranted. [Table: see text]
Collapse
Affiliation(s)
- M. D. Michaelson
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| | - D. P. Cohen
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| | - S. Li
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| | - R. J. Motzer
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| | - B. Escudier
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| | - C. H. Barrios
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| | - P. E. Burnett
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| | - I. Puzanov
- Massachusetts General Hospital Cancer Center, Boston, MA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, Shanghai, China; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Hospital São Lucas da PUCRS, Porto Alegre, Brazil; Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
46
|
|
47
|
Evans T, Lindsay CR, Chan E, Tait B, Michael SA, Day S, Stephens AW, Franke A, Poondru S, Puzanov I. Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2531] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Lawrence DP, Hamid O, McDermott DF, Puzanov I, Sznol M, Clark J, Logan T, Hodi FS, Heller KN, Margolin KA. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8523] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
McArthur GA, Puzanov I, Ribas A, Chapman PB, Kim KB, Sosman JA, Lee RJ, Nolop KB, Flaherty KT, Hicks R. Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8529] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Adjei AA, Sosman JA, Dy GK, Ma W, Fetterly GJ, Skupien D, Means JA, Savage R, Chai F, Puzanov I. A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|